VitalHub Announces Sale to University Hospitals Coventry and Warwickshire NHS Trust
TORONTO, June 09, 2021 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce the recent sale of subsidiary Intouch with Health’s (“Intouch”) digital health platform to University Hospitals Coventry and Warwickshire NHS Trust (the “Trust” or “Coventry and Warwickshire”) and an expansion sale following a successful proof-of-concept installation.
Coventry and Warwickshire is one of the UK's largest teaching Trusts and is responsible for managing two major hospitals in Coventry and Rugby, serving a population of over 1 million people and providing more than 800,000 episodes of care to patients. The Trust principal teaching hospital for Warwick Medical School, with whom it works in close partnership with to develop innovative medical education programmes and clinical research.
The Trust has chosen VitalHub as its digital outpatient partner to assist during the COVID-19 pandemic and beyond. The purchase comprises Intouch’s Check-in, Flow Manager, and Room & Resource healthcare modules, serving to enable the digital transformation for its outpatient department and vastly increase room utilization efficiency. Moreover, these solutions will help the Trust deliver an improved hospital experience for patients while alleviating pressure on its administrators and clinical staff.
Flow Manager is a central digital dashboard accessed by staff across the Outpatient departments throughout the Trust, allowing teams to monitor the location and status of each visiting patient in the department throughout the duration of their appointment. Staff at the Trust will also benefit from Intouch’s Room & Resource Manager module, which allows staff to book and manage the capacity of available rooms across the Outpatient departments to maximise room usage and resources.
“This contract with one of the larger Trusts in the UK provides another example of the market demand for our solutions, and the considerable value they provide to health systems,” said Dan Matlow, CEO of VitalHub Corp. “Increasing demands on hospital services are requiring Trusts to overhaul the way that outpatient journeys are managed for both patients and staff. There is a substantial need to increase operational efficiency, in order to increase capacity, and improve care delivery and the patient experience. We are excited to continue to progress our expansion and growth through the steady accretion of these contracts.”
ABOUT UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST
University Hospitals Coventry and Warwickshire NHS Trust is one of the UK's largest teaching Trusts and is responsible for managing two major hospitals – Hospital of St Cross in Rugby and University Hospital in Coventry – serving a population of over 1 million people and providing more than 800,000 episodes of care to patients. The Trust principal teaching hospital for Warwick Medical School, with whom it works in close partnership with to develop innovative medical education programmes and clinical research.
Software for Health and Human Services providers designed to simplify the user experience & optimize outcomes.
VitalHub provides technology to Health and Human Services providers including; Hospitals, Regional Health Authorities, Mental Health, Long Term Care, Home Health, Community and Social Services. VitalHub solutions span the categories of Electronic Health Record (EHR), Case Management, Care Coordination, Patient Flow & Operational Visibility, and DOCit Mobile Apps.
The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive M&A plan. Currently, VitalHub serves 275+ clients across Canada, USA, UK, Australia, Qatar, and Latvia. VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The Company is publicly traded on the TSX Venture Exchange under the symbol “VHI”.
This press release includes forward-looking statements regarding the Corporation and its business, which may include, but is not limited to, statements with respect to the appointment of a new directors. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the technology industry, failure to obtain regulatory or shareholder approvals, market conditions, economic factors, the equity markets generally and risks associated with growth and competition. Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Corporation undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
Chief Executive Officer, Director
Upcoming Life Sciences Events
- August 2021
- Biotechgate Digital Partnering
- September 2021
- Swiss Biotech Day 2021
- Digital RESI